Neumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement

Reuters

05-17

Neumora <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement

Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450(a)(1). Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-121714), on May 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536328556"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536328556\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536328556?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-17 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536328556","market":"us","top_or_hot":-1,"title":"Neumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450(a)(1). Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-121714), on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-17 04:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450(a)(1). Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-121714), on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NMRA","symbol_name":"Neumora Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL968M94:1","article_id":"2536328556","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536328556","pubTimestamp":1747427245,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450. Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NMRA":"Neumora Therapeutics, Inc.","BK4007":"制药"},"translate_title":"Neumora Therapeutics Inc.因不遵守最低投标价格要求面临纳斯达克退市风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NMRA":0.9},"content_text":"Neumora Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement\n    \n\n        Neumora Therapeutics Inc. has announced a regulatory issue concerning its Nasdaq listing. On May 14, 2025, the company received a notice from The Nasdaq Stock Market LLC indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5450(a)(1). Neumora has 180 days, until November 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. Failure to meet this requirement could lead to potential delisting, although the company may apply for additional time by transferring to The Nasdaq Capital Market. Neumora is considering options to address the issue, including a reverse stock split, which requires stockholder approval.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-121714), on May 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}